Newsroom

DUBLIN, Oct. 24, 2024 /PRNewswire/ -- Mallinckrodt plc ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that it will report third quarter 2024 earnings results for the period ended September 27, 2024, on Tuesday, November 5, 2024. 

A conference call for investors will begin at 8:30 a.m. ET. The call can be accessed as follows:

• Live Call Participant Registration (including dial-in): https://register.vevent.com/register/BI60bb36abdb99465c9db5640f3457528a
• Audio Only Webcast Link (live and replay): https://edge.media-server.com/mmc/p/6tqaksqg/
• At the Mallinckrodt website: https://ir.mallinckrodt.com/

ABOUT MALLINCKRODT
Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The Company's Specialty Brands reportable segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic drugs and active pharmaceutical ingredients. To learn more about Mallinckrodt, visit www.mallinckrodt.com.

Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the Company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission ("SEC") disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.

CONTACTS

Investor Relations
Derek Belz
Vice President, Investor Relations
314-654-3950
derek.belz@mnk.com

Media
Michael Freitag / Aaron Palash / Aura Reinhard / Catherine Simon
Joele Frank, Wilkinson Brimmer Katcher
212-355-4449

^{Mallinckrodt, the "M" brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. © 2024.}

View original content to download multimedia:https://www.prnewswire.com/news-releases/mallinckrodt-to-report-earnings-results-for-third-quarter-2024-302285276.html

SOURCE Mallinckrodt plc